Roche-Action higher: Roche-Krebsmittel Inavolisib is active in the US | 11.10.24

The American healthcare system has developed the drug in combination with Palbociclib (Ibrance) and the complete treatment of patients, an enhanced or metastatic breast cancer with the best mutations.

The FDA has used the test name “FoundationOne Liquid CDx Assay” to identify brusque patients for treatment with inavolisib-zugelassen, part of the US approach to donating. When inavolisib is treated, it is an oral treatment that is very effective.

If Roche’s disease is supported by the INAVO120 phase III trial, inavolisib-based therapy is said to more than double the progression-free rate. The risk of exploring the experience or the todes is that in the standard therapy with palbociclib and fulvestrant you can only choose a 57 Prozent verringert.

This was a man who came across these data – another at the European Arzneimittel-Agentur (EMA), which Genentech, the US-Tochter von Roche, at the Donnerstag in a separate Mitteilung an. Inavolisib was sold very well in the US under the brand name Itovebi “in de kommenden Wochen”.

The medium war as a potential will be expanded, and the US struggle will be promoted sooner. I think it’s good that the FDA made a separation on November 27th.

For the Roche promotion, one of the SIX times is 0.97 Prozent auf 290.80 CHF after receipt.

Basel (awp)